论文部分内容阅读
Dasatinib was identified as potent orally administered Src/Abl kinase inhibitors with excellent antiproliferative activity against Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in chronic phase.The low bioavailability of Dasatinib may be due to both incomplete oral absorption and first-pass metabolism.A series of amino acid derivatives(Ⅰ) as potential prodrugs of Dasatinib were synthesized with the aim of improving aqueous solubility and therapeutic efficacy.The structures of these compounds were determined by IR,1H-NMR,13C-NMR and HRMS spectra.Preliminary in vivo studies indicated that some of derivatives had significantly improved oral bioavailability(~41%,rat) than of the reference drug(Dasatinib,14%),but the result need to get confirmed by further investigations.